Product apis-gpcr-g-protein

Home > products > apis> gpcr-g-protein

Catalog	name	Description	price
R-R-2969	BAY-293 CAS No.2244904-70-7	BAY-293/CAS No.2244904-70-7, a valuable chemical probe, blocks RAS activation via disruption of the KRAS-SOS1 interaction with an IC50 of 21 nM. BAY-293 is a potent inhibitor of Son of Sevenless 1 (SOS1). SOS1 is the guanine nucleotide exchange factor (GEF) and activator of RAS.	price>
R-R-2970	GGTI298 Trifluoroacetate CAS No.1217457-86-7	GGTI298 Trifluoroacetate/CAS No.1217457-86-7 is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, which can inhibit Rap1A with IC50 of 3 μM; little effect on Ha-Ras with IC50 of >20 μM.	price>
R-R-2971	MBQ-167 CAS No.2097938-73-1	MBQ-167/CAS No.2097938-73-1 is a dual Rac/Cdc42 inhibitor, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.	price>
R-R-2972	MRTX0902 CAS No.2654743-22-1	MRTX0902/CAS No.2654743-22-1 is an orally active and potent SOS1 inhibitor with an IC50 of 46 nM (WO2021127429A1; Example 12-10).	price>
R-R-2973	Opnurasib CAS No.2653994-08-0	Opnurasib (JDQ-443) (NVP-JDQ443)/CAS No.2653994-08-0 is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). Opnurasib shows antitumor activity.	price>
R-R-2974	LC-2 CAS No.2502156-03-6	LC-2/CAS No.2502156-03-6 is a potent and first-in-class von Hippel-Lindau-based PROTAC capable of degrading endogenous KRAS G12C, with DC50s between 0.25 and 0.76 μM. LC-2 covalently binds KRAS G12C with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRAS G12C degradation leading to suppression of MAPK signaling in both homozygous and heterozygous KRAS G12C cell lines.	price>
R-C-1275	JNJ 31020028 CAS No. 1094873-14-9	JNJ-31020028 is a selective brain penetrant antagonist of neuropeptide Y2 receptor with high affinity(pIC50=8.07,human;pIC50=8.22 rat);>100-fold selective versus human Y1/Y4/Y5 receptors.	price>
R-R-2975	RMC-6291 CAS No.2641998-63-0	RMC-6291/CAS No.2641998-63-0 is an orally active and covalent inhibitor of KRASG12C(ON). RMC-6291 forms a tri-complex within tumor cells between KRASG12C(ON) and cyclophilin A (CypA). Thus, RMC-6291 prevents KRASG12C(ON) from signaling via steric blockade of RAS effector binding. RMC-6291 inhibits ERK signaling and induced apoptosis in KRASG12C-mutant H358 cells. RMC-6291 also inhibits the proliferation of KRASG12C mutant cells with a median IC50 of 0.11 nM.	price>
R-R-2976	CASIN CAS No.425399-05-9	CASIN/CAS No.425399-05-9 is a selective GTPase Cdc42 inhibitor with an IC50 of 2 uM. CASIN can be used for the research of cancer.	price>
R-R-2977	Salirasib CAS No.162520-00-5	Salirasib/CAS No.162520-00-5 is a Ras inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.	price>

...

163